vTv Therapeutics Inc - Ordinary Shares - Class A

NASDAQ:VTVT  
1.47
-0.03 (-2.00%)
4:14:01 PM EDT: $1.47 0.00 (0.00%)
Regulatory, Earnings Announcements

Vtv Therapeutics Announces Positive Results From Mechanistic Study

Published: 10/12/2021 11:44 GMT
vTv Therapeutics Inc - Ordinary Shares - Class A (VTVT) - Vtv Therapeutics Announces Positive Results From Mechanistic Study Indicating No Increased Risk of Ketoacidosis With Ttp399 During Acute Insulin Withdrawal in Patients With Type 1 Diabetes.
Vtv Therapeutics Inc - Study Achieved Primary Endpoint of Non-inferiority on Measurement of Key Blood Ketone Levels.
Vtv Therapeutics - Patients Taking Ttp399 Reported No Events of Hypoglycemia, While Four Events of Hypoglycemia Were Reported in Placebo Arm.
Vtv Therapeutics - Start-up Activities for Phase 3 Program Ongoing With Trials Expected to Begin in Early 2022.
Revenue is expected to be $1.3 Million
Adjusted EPS is expected to be -$0.07

Next Quarter Revenue Guidance is expected to be $2.8 Million
Next Quarter EPS Guidance is expected to be -$0.07

More details on our Analysts Page.